Target intelligence / Profile preview

Butyrophilin subfamily 2 member A3, pseudogene (BTN2A3P)

Target
BTN2A3P
Molecular classification
Other (pseudogene); does not encode a functional receptor, enzyme, transporter, etc.
01

Overview

BTN2A3P (Butyrophilin subfamily 2 member A3, pseudogene) is a non-protein-coding member of the butyrophilin gene family, localized to chromosome 6 within the human major histocompatibility complex (MHC). Unlike its functional paralogs, BTN2A3P is a pseudogene, so it does not encode a full-length functional protein[2][5]. The butyrophilin gene family is involved with immune modulation and regulation of T cell activity, but BTN2A3P’s precise biological relevance remains undetermined. Some associations link its expression to immune-related tissues and suggest possible involvement in immune response regulation, yet there is no experimental confirmation of a functional protein product or validated disease role. BTN2A3P is not considered a receptor, enzyme, or actionable drug target, and it has no established applications as a biomarker for patient selection or efficacy monitoring[3][5]. Summary: BTN2A3P is a pseudogene—commonly misinterpreted as a protein-coding immune receptor—without evidence for direct biological activity, drug interactions, or therapeutic relevance[2][3][5].

Other names
BTN2A3BTN2.3Butyrophilin, subfamily 2, member A pseudogeneBTN2A3P
02

Biological functions

Other (no known confirmed function; possibly involved in regulatory or non-coding RNA activities; hypothesized involvement in immune system regulation but unconfirmed)
03

Disease associations

Other (no direct disease associations; some studies speculate regulatory roles in autoimmune diseases but this is unverified)

Beyond the preview

Go deeper on Butyrophilin subfamily 2 member A3, pseudogene (BTN2A3P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butyrophilin subfamily 2 member A3, pseudogene (BTN2A3P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call